These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29735363)

  • 1. Host-dependent variables: The missing link to personalized medicine.
    Demlova R; Zdrazilova-Dubska L; Sterba J; Stanta G; Valik D
    Eur J Surg Oncol; 2018 Sep; 44(9):1289-1294. PubMed ID: 29735363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective on Precision Medicine in Oncology.
    Johnson TM
    Pharmacotherapy; 2017 Sep; 37(9):988-989. PubMed ID: 28632968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform.
    Said R; Tsimberidou AM
    Cancer J; 2019; 25(4):282-286. PubMed ID: 31335392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource.
    Kurnit KC; Bailey AM; Zeng J; Johnson AM; Shufean MA; Brusco L; Litzenburger BC; Sánchez NS; Khotskaya YB; Holla V; Simpson A; Mills GB; Mendelsohn J; Bernstam E; Shaw K; Meric-Bernstam F
    Cancer Res; 2017 Nov; 77(21):e123-e126. PubMed ID: 29092956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future Approaches to Precision Oncology-Based Clinical Trials.
    Mittra A; Moscow JA
    Cancer J; 2019; 25(4):300-304. PubMed ID: 31335395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized medicine: CCO's vision, accomplishments and future plans.
    Guo J; Kamel-Reid S; Rutherford M; Hart J; Melamed S; Pollett A
    Healthc Q; 2015; 17 Spec No():41-3. PubMed ID: 25562133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug research in oncology; advances in the genome era].
    Bins S; Schellens JH; Voest EE; Sleijfer S
    Ned Tijdschr Geneeskd; 2014; 158():A6801. PubMed ID: 24618235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethical considerations of neuro-oncology trial design in the era of precision medicine.
    Gupta S; Smith TR; Broekman ML
    J Neurooncol; 2017 Aug; 134(1):1-7. PubMed ID: 28555425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonotyping for precision oncology.
    Dang HX; Maher CA
    Drug Discov Today; 2015 Dec; 20(12):1464-9. PubMed ID: 26494143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety.
    Vignot S; Martin M; Albin N; Schurtz C; Chapel E
    Ann Oncol; 2019 Nov; 30(11):1694-1696. PubMed ID: 31501860
    [No Abstract]   [Full Text] [Related]  

  • 14. Translational medicine promising personalized therapy in oncology.
    Zeng YX; Zhang XS; Liu Q
    Front Med China; 2010 Dec; 4(4):351-5. PubMed ID: 21107749
    [No Abstract]   [Full Text] [Related]  

  • 15. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
    Golan T; Milella M; Ackerstein A; Berger R
    J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic.
    Prudkin L; Nuciforo P
    Cell Oncol (Dordr); 2015 Feb; 38(1):39-48. PubMed ID: 25185990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
    Mandal R; Chan TA
    Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalised cancer medicine.
    Jackson SE; Chester JD
    Int J Cancer; 2015 Jul; 137(2):262-6. PubMed ID: 24789362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated patient and tumor genetic testing for individualized cancer therapy.
    Hertz DL; McLeod HL
    Clin Pharmacol Ther; 2016 Feb; 99(2):143-6. PubMed ID: 26537014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.